Immuneering (IMRX) Current Assets (2020 - 2026)

Immuneering's Current Assets history runs 7 years deep, the most recent figure standing at $161.4 million for Q1 2026.

• In Q1 2026, Current Assets rose 322.47% year-over-year to $161.4 million; the TTM figure through Mar 2026 stood at $161.4 million (up 322.47% YoY), while the FY2025 annual figure was $176.2 million, up 345.21% from the prior year.
• Current Assets was $161.4 million for Q1 2026 at Immuneering, down from $176.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $229.1 million in Q3 2025 to a low of $27.7 million in Q2 2025.
• Historically, Current Assets has averaged $103.4 million across 5 years, with a median of $100.6 million in 2023.
• Biggest YoY gain for Current Assets was 345.21% in 2025; the steepest drop was 56.47% in 2025.
• A 5-year view of Current Assets shows it stood at $108.7 million in 2022, then fell by 18.08% to $89.1 million in 2023, then slumped by 55.56% to $39.6 million in 2024, then soared by 345.21% to $176.2 million in 2025, then dropped by 8.42% to $161.4 million in 2026.
• The last three Current Assets figures came in at $161.4 million (Q1 2026), $176.2 million (Q4 2025), and $229.1 million (Q3 2025), per Business Quant data.